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collected at altitude, did not differ from values at sea level, 
but were markedly lower (p < 0.05) than the mean percent 
migrated isoform (PMI) for the umbilical cord samples.
Conclusion Our studies demonstrate (1) Uc samples 
express a different glycoform distribution as compared to 
adult humans and hence illustrates the ability to synthe-
sis EPO in non-kidney cells during fetal development (2) 
as expected hypoxia augments circulating EPO in adults 
and the predominant source here for remains being kidney 
derived.
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Abbreviations
EPO  Erythropoietin
glc-nAc  N-acetylglucosamine
HA  High altitude
MAIIA  Membrane-assisted isoform immunoassay
PMI  Percent migrated isoform
Sl  Sea level
WgA  Wheat germ agglutinin
Uc  Umbilical cord
Introduction
Erythropoietin (EPO) governs hemoglobin concentration 
and thus arterial oxygen content by regulating red blood 
cell and plasma volumes (Jelkmann 1992; lundby et al. 
2007; Olsen et al. 2011). the classic view is that hypoxia 
stimulates the synthesis and release of EPO in renal peri-
tubular fibroblasts. Work based on HIF-1 knock-out mice 
however suggested that astrocytes, which express both EPO 
and its receptor (Bernaudin et al. 2000), may contribute by 
as much as 50 % to the hypoxia-induced increase in plasma 
Abstract 
Purpose Erythropoietin (EPO) is mainly synthesized 
within renal peritubular fibroblasts, and also other tis-
sues such as the liver possess the ability. However, to 
what extent non-kidney produced EPO contributes to 
the hypoxia-induced increase in circulating EPO in adult 
humans remains unclear.
Methods We aimed to quantify this by assessing the dis-
tribution of EPO glycoforms which are characterized by 
posttranslational glycosylation patterns specific to the 
synthesizing cell. the analysis was performed on samples 
obtained in seven healthy volunteers before, during and 
after 1 month of sojourn at 3,454 m altitude.
Results Umbilical cord (Uc) plasma served as control. 
As expected a peak (p < 0.05) in urine (2.3 ± 0.5-fold) 
and plasma (3.3 ± 0.5-fold) EPO was observed on day 1 
of high-altitude exposure, and thereafter the concentra-
tion decreased for the urine sample obtained after 26 days 
at altitude, but remained elevated (p < 0.05) by 1.5 ± 0.2-
fold above the initial sea level value for the plasma sample. 
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EPO (Weidemann et al. 2009). In divergence hereto we 
observed no detectable release of EPO from the hypoxic 
human brain to the blood stream or to cerebral spinal fluid 
(rasmussen et al. 2012). In contrast to the HIF-1 knock-
out study, however, the samples were obtained after 4 and 
8 h of hypoxic exposure when the erythropoietic response 
to hypoxia may not yet have reached its peak, which is usu-
ally reached within the first 1–3 days of exposure (robach 
et al. 2007).
Besides astrocytes (Masuda et al. 1994) EPO may also 
be synthesized in the liver and based on EPO mrnA 
analysis it is generally accepted that this is the main site 
for EPO production during gestation (Dame et al. 1998; 
Ohls 2002). Adult rodent liver retains its ability to produce 
EPO in response to hypoxia or HIF activation (Fried 1972; 
Kapitsinou et al. 2010; Minamishima and Kaelin 2010). 
Other cells have also been demonstrated to be capable of 
synthesizing EPO although only in minor quantities (Haase 
2010) and accordingly nephrectomized humans demon-
strate elevated EPO levels (Mirand et al. 1968). However, 
to what extent these non-renal EPO production sites con-
tribute to the hypoxia-induced increase in plasma EPO in 
adult humans remains elusive. Since the posttranslational 
glycosylation patterns of the different EPO glycoforms are 
specific to their synthesizing cells (lönnberg et al. 2013; 
Masuda et al. 1994; Wide and Bengtsson 1990), the con-
tribution of the various synthesizing cells to the circulating 
EPO concentration can be determined by analysis hereof. 
In the present study, we analyzed EPO glycoform compo-
sition of healthy humans exposed to altitude for 1 month 
and thereby evaluated the contribution of EPO originating 
from non-kidney cells to the hypoxia-dependent increase 
in circulating EPO. As control we used EPO purified from 
umbilical cord (Uc) samples since the glycosylation pat-
tern observed here most likely differentiates from that seen 
in adults (Wide and Bengtsson 1990). Based on our previ-
ous study conducted in acute hypoxia (rasmussen et al. 
2012), we hypothesized that EPO originating from the 
kidney will remain the main source for circulating EPO in 
hypoxic adult humans.
Methods
Seven healthy male sea-level dwellers with no exposure to 
altitudes above 2,000 m for the last 4 weeks (26 ± 4 years; 
180 ± 1 cm; 76 ± 6 kg) participated in this study which 
was approved by the Ethical committee for the Eidgenös-
sische technische Hochschule Zürich (EK 2011-n-51) and 
conducted in accordance with the declaration of Helsinki. 
Prior to the start of the experiments, informed oral and 
written consents were obtained. After baseline sampling 
in Zürich (480 m) all subjects were transported by train to 
the Jungfraujoch research Station (3,454 m, Bernese Alps, 
Switzerland) where they stayed for 4 consecutive weeks. 
the facilities provide normal living conditions, comfort-
able room temperatures and access to food as consumed at 
sea level.
Urine and venous plasma samples were collected from 
all subjects at sea level (Sl), and then after 1 (HA1; 
17 ± 1 h), 3 (HA3; 65 ± 1 h) and 26 (HA26) days of alti-
tude exposure, and again after 7 (Sl + 7) and 14 (Sl + 14) 
days upon return to sea level. All samples were stored at 
−80 °c.
total plasma EPO concentrations were determined by 
means of a solid-phase sandwich ElISA kit and concentra-
tions were determined based on the standard provided with 
the kit (Human Erythropoietin Quantikine IVD ElISA 
Kit, Quantikine, r&D Systems, Minneapolis, USA). total 
urine EPO concentrations were determined by membrane-
assisted isoform immunoassay (MAIIA) (EPO Quantifi-
cation Urine Kit, MAIIA Diagnostics, Uppsala, Sweden) 
as specified by the manufacturer. In short, 0.5 ml of each 
urine sample was desalted and the EPO concentration 
determined by lateral flow immunoassay (lönnberg et al. 
2008): As reference, a dilution series of epoetin β (provided 
in the kit) ranging from 3 to 1,000 ng l−1 was measured 
by the MAIIA method; the obtained standard curve was fit-
ted with a four-parameter logistic routine and from this the 
EPO concentrations in the urine samples were calculated 
(lönnberg et al. 2012a).
the glycoform heterogeneity of the samples was ana-
lyzed by an EPO WgA MAIIA kit (MAIIA Diagnos-
tics, Uppsala, Sweden) that previously have been used 
for detection of recombinant EPO in humans and horses 
(lönnberg et al. 2012b; lönnberg and lundby 2013; 
Mørkeberg et al. 2013). In the present study we included 
umbilical cord (Uc) plasma, which is known to con-
tain mainly liver-derived EPO (Dame et al. 1998; Ohls 
2002), as positive control for non-renal-derived EPO. For 
detailed description of the procedure refer to lönnberg 
et al. (2012a). In brief, EPO from six Uc plasma samples 
(2 ml) and from the urine samples (20 ml) obtained at Sl, 
HA1, HA3 and HA26 were purified on single-use anti-
EPO columns (EPO Purification Kit, MAIIA Diagnostics, 
Uppsala, Sweden) according to the directions of use. the 
average purification efficiency for the urine samples was 
65 ± 10 %.
the EPO WgA MAIIA isoform distribution kit is based 
on affinity chromatography—with immobilized lectins 
[wheat germ agglutinin (WgA)] interacting with the gly-
cosylated EPO forms and N-acetylglucosamine (glc-nAc) 
used as competing sugar—in combination with lateral 
flow immunoassay. We established the optimal glc-nAc 
concentration to be used in the elution buffer low by run-
ning pilot experiments at four different low glc-nAc 
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concentrations (5, 10 15, and 20 mM) and one high glc-
nAc concentration (300 mM) on samples containing EPO 
purified from Uc and urine. Epoetin β provided in the kit 
was included in all experiments and was used as reference 
(lönnberg et al. 2012a). For the final determination of EPO 
glycoform distribution in the samples, 5 and 300 mM of 
glc-nAc were used in the elution buffers low and high, 
respectively. All samples were run in duplicates and under 
standardized conditions (e.g. temperature, humidity, using 
the same scanner and reagent lot number). the percent 
migrated isoform (PMI) values were calculated as the per-
cent of EPO released by the elution buffer low with respect 
to the total EPO concentration (obtained by elution buffer 
high).
Results and discussion
Umbilical cord EPO and circulating EPO (urine and 
plasma) from healthy subjects gave different PMI values 
at the lower concentrations of glc-nAc (Fig. 1), verifying 
the difference in glycosylation patterns (EPO glycoforms) 
depending on the origin of synthesis.
As expected (Berglund et al. 2002; robach et al. 
2007; Siebenmann et al. 2012) a peak (p < 0.05) in urine 
(2.3 ± 0.5-fold) and plasma (3.3 ± 0.5-fold) EPO was 
observed on HA1 and although reduced from that point 
remained elevated at HA26 for plasma by 1.5 ± 0.2-fold. 
One week after return to sea level also the plasma EPO 
concentrations had returned to Sl values (Fig. 2).
the EPO glycoform heterogeneity, expressed as per-
cent migrated isoforms (PMI) (lönnberg et al. 2012a) in 
the urine samples collected at altitude, did not differ from 
values at Sl, but were markedly lower (p < 0.05) than the 
mean PMI for the umbilical cord samples (Fig. 3). Samples 
containing different EPO glycoforms (e.g. recombinant and 
endogenous EPO) have PMI values that are intermittent 
of the “pure glycoforms” (lönnberg et al. 2012a, b, 2008; 
lönnberg and lundby 2013) and therefore a potential con-
tribution of non-renal-derived EPO to the circulating EPO 
[Glc-NAc] (mM)
5 10 15 20
Pe
rc
en
t M
ig
ra
te
d 
Is
of
or
m
 (%
)
0
20
40
60
80
100
Fig. 1  the percent migrated isoform (PMI) values for umbilical cord 
EPO (closed circles) and circulating EPO from adults (open circles) 
when using different glc-nAc concentrations in the elution buffer 
low. At the low (5 mM) glc-nAc concentration, the difference in PMI 
between the two EPO glycoforms is greatest and due to differences in 
glycolation in the two populations of EPO. Values are mean ± SEM, 
n = 6 for Uc, n = 3 for adults
SL HA 1 HA 3 HA 26 SL+7 SL+14
Pl
as
m
a 
EP
O
 (m
IU
/m
l)
0
10
20
30
40
Ur
in
e 
EP
O
 (n
g/l
)
0
10
20
30
40
*
*
*
*
*
Fig. 2  Plasma (open circles) and urine (filled circles) EPO concen-
trations (mlU ml−1 and ng l−1, respectively) in seven volunteers stud-
ied at sea level (Sl) and after 1 (HA1), 3 (HA3) and 26 (HA26) days 
during exposure to 3,454 m altitude, and again after 7 (Sl + 7) and 
14 (Sl + 14) days upon return to sea level. *P < 0.05 as compared to 
Sl. Values are mean ± SEM
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Fig. 3  EPO glycoform heterogeneity in samples obtained before 
and during acclimatization to high altitude. the PMI values are 
directly related to the glycoform composition of EPO in a given sam-
ple. Hence, for the HA samples an increase in PMI value from Sl 
towards Uc would be a consequence of a sample containing both 
renal and hepatic EPO. Abbreviations as for Fig. 1. Umbilical cord 
(Uc) samples are here shown to have marked higher PMI values. 
*P < 0.05 as compared to the samples obtained in the adult volun-
teers. Values are mean ± SEM
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should have altered the PMI values when comparing Sl 
to HA samples. Since this was not the case in the present 
study, we demonstrate in healthy humans exposed to high-
altitude (3,454 m) hypoxia that the predominant source 
for the rise in plasma EPO is the kidney. Although we did 
not include a control for cnS-derived EPO in the present 
study (currently unavailable), it has been shown that brain-
derived EPO is less glycosylated than renal-derived EPO 
(Masuda et al. 1994), and hence an increase in PMI would 
be expected if more EPO was to be derived from the brain. 
Our findings are in line with previous studies on dogs, 
demonstrating that when exposed to 10 % hypoxia, renal 
venous EPO content was 63 % higher than arterial EPO 
content (Abbrecht and Malvin 1966). Although this does 
not exclude a contribution from other cells, the findings 
suggest a massive contribution of the kidneys to the cir-
culating EPO response to hypoxia. When Bernhardt et al. 
(2010) administrated a prolyl hydroxylase inhibitor, which 
stabilizes HIF expression, kidney transplant patients dem-
onstrated no increase in circulating EPO whereas this was 
the case in healthy volunteers. thus, also from a biochemi-
cal perspective it seems clear that the kidneys are indeed 
the predominant organs responsible for the synthesis of cir-
culating EPO when stimulated by HIF, as expected at high 
altitude. Our study demonstrates the differences in EPO 
glycoform distribution in neonatal umbilical cord samples 
as compared to adults, and thereby extends previous tis-
sue mrnA work (Dame et al. 1998; Ohls 2002) suggesting 
liver cells to be the main site for EPO synthesis during ges-
tation. thus, although the human liver in the neonatal state 
has an important role in the synthesis of EPO and although 
astrocyte-derived EPO may account for up to 50 % of the 
erythropoietic response in mice when exposed to hypoxia, 
this does not seem to be relevant for the circulating EPO 
levels in healthy adult humans when exposed to continuous 
hypoxia.
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